Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease

Behçet Disease Clinical Trial

— STELABEC  

Official title:

A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02648581
• Other study ID #: P140302
• Status: Completed
• Phase: Phase 2
• Start date: June 14, 2017
• Est. completion date: November 19, 2019

Study information

• Verified date: November 2021
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the proof of concept of efficacy of ustekinumab in subjects with Behçet disease, including patients with oral ulcers (STELABEC-1) and patients with active posterior uveitis or panuveitis (STELABEC-2)

Description:

Behçet disease (BD) is a chronic systemic inflammatory disorder at the crossroad between autoimmune and autoinflammatory syndromes. Two recent large genome-wide association studies (GWAS) conducted in Turkey and Japan reported association between single nucleotide polymorphism (SNP) of interleukin (IL)-10 and IL-23R/IL-12RB2 genes and BD. Interleukin-12 and interleukin-23, cytokines that induce naive CD4+ lymphocytes to differentiate into type 1 helper T cells (Th1 cells) and type 17 helper T cells (Th17 cells), respectively, have been identified as key mediators of BD. Promotion of Th1 and Th17 responses and suppression of regulatory T cells correlate with BD activity. Due to the lack of an etiologic agent, the treatment is symptomatic without consensus. The goals are the functional recovery of a visceral involvement (eye, central nervous system) and prevention of relapse(s). The risks of BD are an increased mortality especially in case of arterial involvement, and a high morbidity due to the cumulative sequelae of ocular and neurological involvement. Steroids are the corner stone of the antiinflammatory agents administered topically or systemically. Relapses are frequently seen after discontinuation of steroids, and corticodependence is frequently observed leading to the use of immunosuppressive drugs. Biologic agents that selectively block steps in the inflammatory cascade could provide additional therapies for BD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: November 19, 2019
• Est. primary completion date: May 7, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Are at least 18 years of age.

2. Have a diagnosis of BD according to the International Classification Criteria (criteria from the International Study Group and/or the 2013 International Criteria for BD).

3. Have an active disease at screening, defined by the presence of :

For the STELABEC-1 study : Recurrent oral and/or genital ulcers, defined as =2 episodes within 3 months before study entry. Before study entry, patients should have at least 2 oral ulcers within the last 2 weeks before baseline visit. For the STELABEC-2 study : Active posterior uveitis and/or panuveitis and/or retinal vasculitis, defined by the presence of at least 1 or the following parameters in at

least one eye :

• Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion
• =2+ anterior chamber cells (Standardization of Uveitis Nomenclature [SUN] criteria)
• =2+ vitreous haze (National Eye Institute [NEI]/SUN criteria)

4. Have previously received at least 1 non-biologic therapy :

For the STELABEC-1 study : Colchicine =1 mg/day for all patients For the STELABEC-2 study : Subjects must have active disease at the baseline visit despite at least 2 weeks of oral prednisone = 10 mg/day to =60 mg/day (or oral corticosteroid equivalent) with or without prior high dose corticoid pulse.

5. Are without treatment regimen (due to ineffectiveness / intolerance) or on a stable BC treatment regimen consisting of any of the following medications (alone or in combination) : Corticosteroids for a period of at least 2 weeks prior to Day 0 Colchicine for a period of at least 30 days prior to Day 0 Immunosuppressive or immunomodulatory agents for a period of at least 30 days prior to Day 0 Thalidomide for a period of at least 60 days prior to Day 0

6. A female subject is eligible to enter the study if she is :

• Not pregnant or breast-feeding
• Of non-childbearing potential (ie, women who had a hysterectomy, are postmenopausal which is defined as 1 year without menses, have both ovaries surgically removed or have current documented tubal ligation); or
• Of childbearing potential (ie, women with functional ovaries and no documented impairment of oviductal or uterine function that would cause sterility). This category includes women with oligomenorrhoea [even severe], women who are perimenopausal or have just begun to menstruate. These women must have a negative serum pregnancy test at screening, and agree to 1 of the following : Complete abstinence from intercourse from 2 weeks prior to administration of the 1st dose of study agent until 8 weeks after the last dose of study agent; or Consistent and correct use of 1 of the following acceptable methods of birth control for 1 month prior to the start of the study agent and 15 weeks after the last dose of

study agent :

• Implants of levonorgestrel;
• Injectable progesterone;
• Any intrauterine device (IUD) with a documented failure rate of less than 1% per year;
• Oral contraceptives (either combined or progesterone only);
• Double barrier method: Condom, cervical cap or diaphragm with spermicidal agent;
• Transdermal contraceptive patch;
• Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for the female subject.

7. Have the ability to understand the requirements of the study provide written informed consent (including consent for the use and disclosure of research-related health information) and comply with the study protocol procedures (including required study visits).

8. Affiliation with a mode of social security (profit or being entitled)

Exclusion Criteria:

• Have required 3 or more courses of systemic corticosteroids for concomitant conditions (eg, asthma, atopic dermatitis) within 90 days of Day 0 (Topical or inhaled steroids are permitted)
• Have received intravenous (IV) or oral cyclophosphamide within 180 days of Day 0.
• Have received any of the following within 90 days of Day 0 :

Anti-TNF therapy (eg, adalimumab, etanercept, infliximab). Interleukin-1 receptor antagonist (anakinra). Abatacept Interleukin-6 receptor antagonist (tocilizumab) Intravenous immunoglobulin (IVIG) High dose prednisone (> 100 mg/day).

• Have received any of the following within 60 days of Day 0 :

A non-biologic investigational agent. Any new immunosuppressive/immunomodulatory agent. Any steroid injection (intramuscular, intraarticular or intravenous).

• Have received any of the following within 30 days of Day 0 :

A live vaccine within 30 days of Day 0. A change in dose of a corticosteroid within 2 weeks days of Day 0. A change in dose of other immunosuppressive/immunomodulatory agent within 30 days of Day 0.

• Have very severe Behc¸et disease (defined by current severe complication of BD:

digestive, cardiac, pulmonary or central nervous system involvement assessed as very severe by the referring clinician) requiring high dose prednisone (=1mg/kg) within 30 days of Day 0 (with the exception of high dose prednisone pulse for active uveitis)

• Have a history of a major organ transplant (eg, heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.
• Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to BD which, in the opinion of the principal investigator, could confound the results of the study or put the subject at undue risk.
• Have a planned surgical procedure or a history of any other.
• Medical disease, laboratory abnormality, or condition that, in the opinion of the principal investigator, makes the subject unsuitable for the study.
• Have a history of malignant neoplasm within the last 5 years, except for treated cancers of the skin or carcinoma in situ of the uterine cervix.
• Have required management of acute or chronic infections :
• Currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria).
• Hospitalization for treatment of infection within 60 days of Day 0.
• Use of parenteral (IV or IM) antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents) within 60 days of Day 0.
• Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Day 0.
• Have a historically positive test or test positive at screening for HIV-1 antibody, hepatitis C virus antibodies, hepatitis B surface antigen (HbsAg), or antiHBcAg positivity (without HbsAg positivity).
• Have a Grade 3 or greater laboratory abnormality based on the protocol toxicity scale

except for the following that are allowed:

• Stable Grade 3 prothrombin time (PT) secondary to warfarin treatment.
• Stable Grade 3/4 proteinuria (= 6 g/24 hour equivalent by spot urine protein to creatinine ratio allowed).
• Stable Grade 3 neutropenia or stable Grade 3 white blood cell count.
• Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.

Related Conditions & MeSH terms

• Behçet Disease
• Behcet Syndrome

Intervention

Drug:
• Subcutaneous Ustekinumab
Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.

Locations

Country	Name	City	State
France	Hôpital Cochin, Department of Internal Medicine, National Reference Center for Autoimmune and Systemic Diseases	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of oral ulcers at week 24 compared to baseline	Treatment efficacy at week 24 for STELABEC-1 study on oral ulcers	24 weeks
Primary	Number of uveitis or retinal vasculitis remission	Treatment efficacy at week 24 for STELABEC-2 study on eye involvement	24 weeks
Secondary	Number of oral and genital ulcers		at baseline visit (week 0)
Secondary	Number of oral and genital ulcers		4 weeks
Secondary	Number of oral and genital ulcers		8 weeks
Secondary	Number of oral and genital ulcers		12 weeks
Secondary	Number of oral and genital ulcers		16 weeks
Secondary	Number of oral and genital ulcers		24 weeks
Secondary	Number of oral and genital ulcers		28 weeks
Secondary	Number of oral and genital ulcers		40 weeks
Secondary	Number of oral and genital ulcers		52 weeks
Secondary	Pain Visual Analog Scales of oral and genital ulcers		at baseline visit (week 0)
Secondary	Pain Visual Analog Scales of oral and genital ulcers		4 weeks
Secondary	Pain Visual Analog Scales of oral and genital ulcers		8 weeks
Secondary	Pain Visual Analog Scales of oral and genital ulcers		12 weeks
Secondary	Pain Visual Analog Scales of oral and genital ulcers		16weeks
Secondary	Pain Visual Analog Scales of oral and genital ulcers		24 weeks
Secondary	Pain Visual Analog Scales of oral and genital ulcers		28 weeks
Secondary	Pain Visual Analog Scales of oral and genital ulcers		40 weeks
Secondary	Pain Visual Analog Scales of oral and genital ulcers		52 weeks
Secondary	Number of chorioretinal and/or inflammatory retinal vascular lesions, inflammation in anterior chamber and in vitreous haze		baseline visit (week 0)
Secondary	Number of chorioretinal and/or inflammatory retinal vascular lesions, inflammation in anterior chamber and in vitreous haze		4 weeks
Secondary	Number of chorioretinal and/or inflammatory retinal vascular lesions, inflammation in anterior chamber and in vitreous haze		8 weeks
Secondary	Number of chorioretinal and/or inflammatory retinal vascular lesions, inflammation in anterior chamber and in vitreous haze		12 weeks
Secondary	Visual acuity by Early Treatment Diabetic Retinopathy Study (ETDRS)		16 weeks
Secondary	Number of chorioretinal and/or inflammatory retinal vascular lesions, inflammation in anterior chamber and in vitreous haze		24 weeks
Secondary	Number of chorioretinal and/or inflammatory retinal vascular lesions, inflammation in anterior chamber and in vitreous haze		28 weeks
Secondary	Number of chorioretinal and/or inflammatory retinal vascular lesions, inflammation in anterior chamber and in vitreous haze		40 weeks
Secondary	Number of chorioretinal and/or inflammatory retinal vascular lesions, inflammation in anterior chamber and in vitreous haze		52 weeks
Secondary	Behc¸et Syndrome Activity Score (BSAS)		12 weeks
Secondary	Behc¸et Disease Current Activity Form (BDCAF)		12 weeks
Secondary	Behc¸et Syndrome Activity Score (BSAS)		24 weeks
Secondary	Behc¸et Disease Current Activity Form (BDCAF)		24 weeks
Secondary	Behc¸et Syndrome Activity Score (BSAS)		52 weeks
Secondary	Behc¸et Disease Current Activity Form (BDCAF)		52 weeks
Secondary	Behc¸et Disease Quality of Life Measure : Short Form-36 (SF- 36)		12 weeks
Secondary	Behc¸et Disease Quality of Life Measure : Routine Assessment of Patient Index Data 3 (RAPID3)		12 weeks
Secondary	Behc¸et Disease Quality of Life Measure : Short Form-36 (SF- 36)		24 weeks
Secondary	Behc¸et Disease Quality of Life Measure : Routine Assessment of Patient Index Data 3 (RAPID3)		24 weeks
Secondary	Behc¸et Disease Quality of Life Measure : Short Form-36 (SF- 36)		52 weeks
Secondary	Behc¸et Disease Quality of Life Measure : Routine Assessment of Patient Index Data 3 (RAPID3)		52 weeks
Secondary	Number of adverse events	adverse events including headache, arthralgia, infection (pneumonia and bronchitis),skin infections, shingles, depression, dizziness, diarrhea, pruritus, myalgia, asthenia	from baseline visit up to 52 weeks